318 related articles for article (PubMed ID: 36571995)
1. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y
Yuan Y; Yan Z; Lao Q; Jiang N; Wu S; Lu Q; Han J; Zhao S
Eur J Med Chem; 2023 Feb; 247():115036. PubMed ID: 36571995
[TBL] [Abstract][Full Text] [Related]
2. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
3. Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y
Yang Q; Tang W; Sun L; Yan Z; Tang C; Yuan Y; Zhou H; Zhou F; Zhou S; Wu Q; Song P; Fang T; Xu R; Han J; Jiang N
J Med Chem; 2022 Oct; 65(20):14201-14220. PubMed ID: 36214844
[TBL] [Abstract][Full Text] [Related]
4. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.
Zhang X; Cai Y; Yao Z; Chi H; Li Y; Shi J; Zhou Z; Sun L
Peptides; 2023 Mar; 161():170948. PubMed ID: 36646385
[TBL] [Abstract][Full Text] [Related]
6. Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity.
Li Q; Yang Q; Han J; Liu X; Fu J; Yin J
Chin J Nat Med; 2022 Nov; 20(11):863-872. PubMed ID: 36427920
[TBL] [Abstract][Full Text] [Related]
7. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
8. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
[TBL] [Abstract][Full Text] [Related]
9. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
10. Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists.
Jiang N; Jing L; Li Q; Su S; Yang Q; Zhou F; Chen X; Han J; Tang C; Tang W
Eur J Med Chem; 2021 Feb; 212():113118. PubMed ID: 33422984
[TBL] [Abstract][Full Text] [Related]
11. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
13. Engineering a potent and long-acting GLP-1/Y
Xu J; Wang S; Wu H; Chen D; Han J; Lin Q
Peptides; 2023 Nov; 169():171073. PubMed ID: 37536423
[TBL] [Abstract][Full Text] [Related]
14. Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors.
Vishnoi S; Bhattacharya S; Walsh EM; Okoh GI; Thompson D
J Chem Inf Model; 2023 Aug; 63(15):4934-4947. PubMed ID: 37523325
[TBL] [Abstract][Full Text] [Related]
15. Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists.
Darbalaei S; Chang RL; Zhou QT; Chen Y; Dai AT; Wang MW; Yang DH
Acta Pharmacol Sin; 2023 Feb; 44(2):421-433. PubMed ID: 35953646
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
[TBL] [Abstract][Full Text] [Related]
17. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
18. A GLP-1/glucagon (GCG)/CCK
Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N
Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823
[TBL] [Abstract][Full Text] [Related]
19. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
[TBL] [Abstract][Full Text] [Related]
20. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
